HR-6182-119
Referred to the Subcommittee on Health.
Sponsored by Rosa DeLauro (D-CT)
What it does
The Find It Early Act would require health insurers, Medicare, Medicaid, TRICARE, and the VA to cover additional breast cancer screening and diagnostic imaging — including mammograms, ultrasounds, MRI, and other technologies — at no cost to patients. Coverage would apply to individuals deemed at increased risk for breast cancer or with dense breast tissue (per American College of Radiology criteria), as well as to individuals whose provider determines they need screening based on age, race, ethnicity, or personal or family medical history. The bill would take effect January 1, 2026, and would also apply to grandfathered health plans that are currently exempt from many ACA coverage mandates.
Who benefits
Women and others at elevated breast cancer risk who currently face cost-sharing for supplemental screenings beyond standard mammograms. Individuals with dense breast tissue, who are at higher cancer risk but often face out-of-pocket costs for recommended follow-up imaging. Black and Hispanic women, who face higher rates of dense breast tissue and aggressive breast cancer subtypes. Veterans with breast cancer risk factors, including those not currently enrolled in the VA patient enrollment system. Military families covered by TRICARE. Radiology providers and imaging centers that may see increased utilization. Breast cancer advocacy organizations. Early-stage cancer patients who may benefit from earlier detection and less costly treatment.
Who is hurt
Private insurers and employer-sponsored health plans that would absorb the cost of newly mandated no-cost screenings. Employers offering self-insured plans subject to ERISA, who would face increased plan costs. Taxpayers who fund Medicare, Medicaid, TRICARE, and VA programs, which would bear additional spending. Grandfathered health plan holders, whose plans would lose a longstanding exemption from new coverage mandates. Insurers in states with lower-cost benchmark Medicaid plans, who would be required to expand coverage. Potentially, all insured individuals, if insurers respond by raising premiums to offset the cost of the new mandate.
Supporters argue
Supporters argue that breast cancer is the most commonly diagnosed cancer among American women, and that cost-sharing is a documented barrier to supplemental screening — particularly for the roughly 40% of women who have dense breast tissue and require imaging beyond a standard mammogram. They contend that earlier detection reduces both mortality and the cost of treatment, citing research showing that stage I breast cancer treatment costs a fraction of stage IV treatment. They further argue that the bill closes an inequity, as Black women are 40% more likely to die from breast cancer than white women despite similar incidence rates, and that removing financial barriers to recommended screening directly addresses that disparity.
Opponents argue
Opponents argue that mandating no-cost coverage for all provider-recommended supplemental screenings — without a uniform federal clinical threshold — could drive overutilization, unnecessary follow-up procedures, and patient anxiety from false positives, outcomes documented in studies of expanded mammography programs. They contend that delegating coverage determinations to evolving National Comprehensive Cancer Network and American College of Radiology guidelines, rather than to the U.S. Preventive Services Task Force, bypasses the established federal evidence review process and could expose insurers to open-ended, unpredictable cost obligations. They further argue that the resulting premium increases would be borne broadly by all policyholders, effectively redistributing costs to individuals who may never need the covered services.